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Introduction
Immune response–associated inflammation is pivotal in protecting 
the host against foreign pathogens; however, if left unrestrained, it 
can cause deleterious and often irreversible damage to tissues and 
organs. Although initiation of inflammatory responses is primarily 
caused by infection or injury, a variety of autoimmune diseases and 
cancers can promote chronic inflammation (1). If left unchecked, 
continuous exposure to proinflammatory soluble mediators, such 
as TNF-α, IL-17, IL-6, and IFN-α, contributes to the pathogenesis 
of several autoimmune and inflammatory disorders, including 
rheumatoid arthritis (RA), multiple sclerosis (MS), and system-
ic lupus erythematosus (SLE) (2). To avoid irreversible damage, 
prompt generation of an antiinflammatory cellular response that 
minimizes tissue injuries and promotes restoration of homeostasis 
is required (3). Multiple regulatory pathways that prevent further 
lymphocytic hyperactivation and restrain existing inflammatory 
signals are in place to restore immune homeostasis.
In addition to the well-established contribution of Tregs in the 
maintenance of immune homeostasis, B cells producing IL-10, 
known as regulatory B cells (Bregs), have been shown to contrib-
ute to the maintenance of tolerance (4–6). Immunosuppressive 
Bregs that express IL-10 and other antiinflammatory mediators 
are involved in the maintenance of homeostasis in the immune 
system. The importance of Bregs is emphasized by the different 
immune-related pathologies that are associated with abnormalities 
in the number and function of Bregs (4, 6–11). For these reasons, 
there is increasing interest in better understanding the biology of 
Bregs and identifying the signals that induce their differentiation in 
order to exploit their therapeutic potential. This Review summariz-
es the role of human Bregs in health and different disease settings. 
We also discuss possible Breg-directed therapeutic strategies that 
could provide ways of reshaping and resetting the immune system 
for improved treatment of various diseases.
Mechanism of suppression
Bregs are indispensable for the maintenance of tolerance and 
immune homeostasis, despite representing fewer than 10% of B 
cells in circulation in healthy individuals (4). Breg-mediated sup-
pression occurs primarily via the production of IL-10; therefore, 
IL-10 is often used as a marker for Breg identification. Detection 
of IL-10 by intracellular staining makes it difficult to conduct a 
functional assessment of Bregs; hence other cell surface markers 
are used to identify “surrogate” Bregs and Breg precursors. Here, 
we define Bregs as IL-10–producing B cells or B cells that exhibit 
immune suppression. It is important to note that the identification 
of Bregs in vitro requires additional stimulation, as IL-10–produc-
ing Bregs cannot be identified directly ex vivo. The signals required 
for Breg differentiation are discussed in the section below.
Multiple subsets of B cells that produce IL-10, often with over-
lapping surface markers but diverse functions, have been reported 
and are collectively referred to as Bregs (12). These include IL-10–
producing CD24hiCD38hi B cells, CD24hiCD27+ B cells (B10), 
CD38+CD1d+IgM+CD147+GrB+ B cells, CD27intCD38hi plasmab-
lasts, and CD19+TIM1+ B cells, which have all been shown to sup-
press proinflammatory responses (4, 13–16). Notably, fewer than 
20% of the B cells within these different B cell subsets produce 
IL-10 and suppress immune responses. IL-10–producing Bregs, 
most of which express CD24, CD1d, and variable levels of CD27, 
inhibit the activation of Th1 responses, inhibit the differentiation 
of Th17 cells, and can also convert CD4+ T cells into suppressive 
Tregs and type 1 regulatory (Tr1) cells (4, 6). Although IL-10 is the 
primary cytokine required for suppression, the engagement of 
CD80 and CD86 on Bregs enhances the inhibition of Th1 respons-
es (4, 6). In addition to CD4+ T cells, IL-10+ Bregs inhibit IFN-γ 
production by CD8+ T cells in response to hepatitis B virus (HBV) 
infection (17), and suppress TNF-α production following stimu-
lation with LPS and bacterial CpG DNA by activating monocytes 
(13). More recently, it has been shown that in healthy individuals, 
Bregs suppress production of the antiviral cytokine IFN-α in plas-
macytoid dendritic cells (pDCs) via the release of IL-10, suggest-
ing that Bregs are involved in the prevention of collateral damage 
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CD39+CD73+ Bregs inhibit CD4+ and CD8+ T cell proliferation 
via the production of 5′-AMP (22). It is noteworthy that although 
not yet described in human studies, IL-35 has been shown to be 
important in Breg-mediated suppression. In a mouse model of MS, 
experimental autoimmune encephalomyelitis (EAE), mice lacking 
B cell–specific IL-35 production developed exacerbated disease 
and also displayed improved resistance to Salmonella infection 
(23). The growing number of suppressive mechanisms ascribed to 
Bregs suggests that Bregs play a multifaceted role in immune reg-
ulation. The diverse mechanisms of immune suppression by Bregs 
are summarized in Table 1.
Signals required for Breg differentiation
In order to be activated and exhibit suppressive functions, Bregs 
require the engagement of combinations of several molecules, 
including TLR, CD40, and/or B cell receptor (BCR), as well as 
CD80, CD86, and cytokine receptors. While the majority of 
evidence demonstrating the relevance of costimulatory signals, 
TLRs, and cytokines comes from murine studies, several of these 
signals have also been found necessary for the differentiation of 
Bregs in humans. It is noteworthy that to detect a distinct popula-
tion of IL-10–expressing B cells in vitro using flow cytometry, an 
additional robust stimulation with phorbal 12-myristate 13-ace-
tate, ionomycin, and brefeldin A is used, either alone or in com-
bination with other stimuli. Signals controlling the activation of 
Bregs have been discussed in detail elsewhere (24) and are sum-
marized here in Figure 1.
that is caused by unresolved infections (18). Finally, B regulatory 1 
(Br1) cells, identified as CD25hiCD71hiCD73lo B cells, contribute 
to the maintenance of allergen tolerance by producing a copious 
amount of allergen-specific IgG4 antibodies and by suppressing 
allergen-specific T cell proliferation (19).
Like other immunosuppressive cells, such as Tregs, B cells 
can differentiate into induced Bregs (iBregs) in response to cer-
tain stimuli. It has been previously shown that T cells expressing 
cytotoxic T lymphocyte–associated protein 4 (CTLA-4) promote 
the differentiation of a population of iBregs that modulate immune 
responses via the production of TGF-β and indoleamine 2,3-dioxy-
genase (IDO), which can convert the interacting T cells into IL-10– 
and TGF-β–producing Tregs (20). Although the importance of 
CTLA-4–expressing T cells in the differentiation of Bregs remains 
to be ascertained, it is possible that this mechanism of expansion 
exists in vivo as a way to guarantee immunosuppression in the pres-
ence of excessive inflammation. Furthermore, CD1d-mediated lip-
id antigen presentation by IL-10–producing CD24hiCD38hi B cells 
(CD24hiCD38hi Bregs) is important for maintaining the number 
and function of induced NKT cells (iNKT cells), a cell subset with 
immunosuppressive capacity (21).
CD39+CD73+ B cells drive a shift from an ATP-driven proin-
flammatory environment to an adenosine-induced antiinflam-
matory milieu (22). CD39 and CD73 are ectonucleotidases that 
can hydrolyze exogenous adenosine triphosphate (ATP) to ade-
nosine 5′-monophosphate (5′-AMP) and adenosine. It has been 
suggested that upon in vitro activation with CD40L and IL-4, 
Table 1. Mechanisms of human Breg–mediated suppression
Subtype Phenotype Mechanism of suppression Target of suppression References
Immature B cells CD24hiCD38hi IL-10, PD-L1, CD80, CD86, CD1d CD4+ T cells, CD8+ T cells, pDCs, iNKT cells 4, 18, 21, 59
B10 cells CD24hiCD27+ IL-10 Monocytes 13
GZMB+ B cells CD38+CD1d+IgM+CD147+ GZMB, IL-10, IDO CD4+ T cells 14
Br1 cells CD25hiCD71hiCD73lo IL-10, IgG4 CD4+ T cells 19
Plasmablasts CD27intCD38hi IL-10 – 15
– CD39+CD73+ Adenosine CD4+ T cells, CD8+ T cells 22
iBregs – TGF-β, IDO CD4+ T cells 20
– CD19+TIM1+ IL-10 CD4+ T cells, CD8+ T cells 16
 
Figure 1. Induction of Bregs. IL-10–producing 
Bregs that express regulatory genes are generat-
ed as a consequence of immune activation. The 
signals that induce the differentiation of Bregs 
include inflammatory stimuli (via TLRs), costim-
ulatory signals (CD40, CD80, CD86), microbiota, 
and cytokines (IFN-α/β, IL-1β, IL-6, IL-21, and 
BAFF).
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play impaired IL-10–producing capacity upon CD40 activation, 
and are unable to suppress Th1 responses (4, 40). Independently, 
another study demonstrated that large CD19+FSChi polyclonally 
activated B cells (iBregs) from SLE patients display a significant-
ly reduced ability to suppress Th cell responses compared with B 
cells from healthy individuals (41). Additionally, stimulation with 
TLR9-activated pDCs induces a multifold expansion of immuno-
suppressive IL-10–producing CD24+CD38hi Bregs in healthy indi-
viduals but not SLE patients (18).
Our group has recently identified the reason for the loss of 
Breg function in patients with SLE, an autoimmune disease char-
acterized by increased IFN-α levels and an IFN-α–induced gene 
signature (18). Our results indicate that the level of exposure to 
the proinflammatory cytokine IFN-α is important in determining 
immature B cell fate: whereas low concentration of IFN-α simulta-
neously expands both Bregs and plasmablasts, high concentration 
of IFN-α skews B cell differentiation in favor of plasmablasts but 
fails to expand Bregs (18). In these patients, increased IFN-α signal-
ing is mirrored by a loss of functional Bregs as well as an increase 
in autoantibody-producing plasma cells that contribute to disease 
pathogenesis (18). Further analysis revealed that the Breg defects 
were also associated with alterations in phosphorylation of signals 
downstream of the IFN-α/β receptor, namely STAT1 and STAT3 
(18, 42). This is most likely due to chronic exposure to IFN-α in 
vivo. In addition, functionally impaired CD24hiCD38hi Bregs iso-
lated from patients with SLE fail to restrain IFN-α production by 
hyperactivated pDCs (18). This suggests that the immune-regula-
tory pDC-Breg feedback loop that is in place in healthy individuals 
is dysfunctional in SLE patients.
Because of the multiple abnormalities in the B cell compart-
ment in SLE and their hypothesized role in SLE pathogenesis, 
patients are often treated with rituximab (B cell depletion) therapy 
(43, 44). Upon B cell repopulation, a higher immature-to-memory 
ratio has been associated with long-term remission (45, 46), sug-
gesting that repopulation with CD24hiCD38hi Bregs might be asso-
ciated with improved clinical response. This concept is supported 
by independent studies evaluating SLE patients treated with rit-
uximab in which the repopulation of CD24hiCD38hi Bregs with 
restored suppressive functions corresponded with an improved 
clinical response (18, 21). Patients responding to rituximab thera-
py display normal STAT1 and STAT3 activation and have restored 
IL-10 production by repopulated B cells (18). Furthermore, the 
restored CD24hiCD38hi Breg function corresponded to normal-
ized activation of pDCs that were otherwise hyperactivated in SLE 
patients (18). Another study evaluating the iNKT cell response in rit-
uximab-treated SLE patients provides further evidence for the role 
of Bregs in the improved clinical response. iNKT cells are scarcely 
present in patients with SLE, and we and others have shown that 
this is due to dysfunctional interactions with aberrant B cells (21, 
47). However, following B cell repopulation, normalization of CD1d 
expression on newly repopulated CD19+CD24hiCD38hi B cells cor-
responded with normalization of the iNKT cell number and func-
tion (21), suggesting that Bregs are important in the maintenance 
of homeostatic levels of iNKT cells. Taken together, these in vitro 
studies suggest that newly repopulated Bregs in SLE patients might 
suppress inflammation by empowering several other cells of the 
immune system with immunosuppressive functions.
Role in disease
Autoimmunity. Numerical and functional Breg defects have been 
described in several autoimmune diseases, including SLE, RA, 
MS, and psoriasis (4, 6, 21, 25, 26). Multiple studies have identi-
fied inverse correlations between Breg numbers and function and 
disease activity. In the context of autoimmunity, this raises two 
possible scenarios. First, the loss of immune suppression driven by 
Bregs contributes to inflammation. The second scenario is that the 
reduced Breg numbers and function are a consequence of chronic 
inflammation. Because of the current limitations of human Breg 
studies, evidence supporting either scenario needs to be extrap-
olated entirely from murine studies. Chimeric mice with IL-10 
deficiency specific to B cells have been shown to develop exacer-
bated arthritis as well as EAE due to increases in Th1 and/or Th17 
responses compared with WT mice (27, 28). Furthermore, adop-
tive transfer of mouse Breg subsets has been shown to suppress 
various autoimmune diseases, including arthritis, EAE, and lupus 
(5, 29–31). It is noteworthy that inflammatory signals have been 
reported to expand functional Bregs, rather than reduce numbers 
(32, 33). Novel therapeutics specifically targeting Bregs will help 
address these remaining questions in the future.
Multiple sclerosis. Suppressive B cells were first identified in 
patients with MS: MS patients infected with helminths displayed 
an increased frequency of IL-10–producing CD19+CD1dhi B cells 
as well as a better clinical outcome. The B cells isolated from 
MS patients with helminth infection suppressed proliferation 
and IFN-γ production by T cells (34). Although in human stud-
ies, it is difficult to conclusively establish the exact mechanism 
of action, the amelioration of disease symptoms in helminth- 
infected MS patients was speculated to be due to the expansion 
of IL-10–producing B cells. More recently, in relapsing-remitting 
MS (RRMS), a reduction in IL-10–producing B cells was found in 
patients experiencing relapse compared with patients in remis-
sion and compared with healthy individuals (25). Interestingly, 
IFN-β therapy, a treatment for RRMS, has been shown to work via 
the expansion of CD24hiCD38hi Bregs in patients (35). In the same 
study, the authors took advantage of an experimental model of 
MS to show that while WT mice respond to IFN-β therapy, B cell–
deficient mice were refractory to the same therapeutic regime, 
confirming that B cells mediate the antiinflammatory effects 
of IFN-β therapy (35). Similarly, other studies have reported an 
expansion of Breg phenotype and function upon treatment of MS 
patients with fingolimod (a sphingosine-1-phosphate modulator) 
and alemtuzumab (an anti-CD52 therapy) (36–38). Furthermore, 
rituximab therapy in MS patients has been shown to improve clin-
ical response by ablating pathogenic IL-6–producing B cells (39). 
Taken together, immunomodulatory treatments in MS patients 
might work, in part, by inducing a shift in B cells toward a more 
antiinflammatory phenotype.
Systemic lupus erythematosus. Patients with active SLE are 
characterized by a numerical and functional deficiency in circu-
lating Bregs. Several studies have now shown that the defect is 
associated with the inability of immature (CD19+CD24hiCD38hi) 
B cells to differentiate into Bregs in response to signals known to 
be pivotal for their differentiation (4, 18, 40, 41). Whereas healthy 
immature B cells respond to CD40 stimulation and differentiate 
into Bregs, CD24hiCD38hi B cells isolated from SLE patients dis-
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(16). A more recent study showed that Bregs inhibit antigen presen-
tation and CD4+ T cell proliferation and impair anti-HIV cytotoxic 
T lymphocyte functions in HIV-infected patients via the release of 
IL-10 and PD-1/PD-L1 interaction (60). Similarly, in patients with 
chronic HBV, there was an expansion of IL-10–producing CD24hi 
CD38hi B cells, and their frequency correlated with hepatic flares. 
CD24hiCD38hi Bregs were found to suppress HBV-specific CD8+ 
T cell responses in an IL-10–dependent manner (17). CD24hiCD38hi 
Bregs in chronic HBV patients suppress Th1 and Th17 responses as 
well as convert CD4+ T cells into Tregs (61). Taken together, these 
studies implicate a role for CD24hi CD38hi Bregs in hindering viral 
eradication during an infection.
Allergy. Bregs have been shown to play a role in allergen toler-
ance and contribute to the suppression of various allergic diseas-
es. In patients with allergic asthma, a reduced expansion of IL-10–
producing CD24hiCD27+ Bregs was reported in response to LPS 
stimulation (8). Moreover, LPS-stimulated B cells from patients 
induced a weaker IL-10 response by dust mite allergen–activated 
T cells. A similar reduction in the frequency of IL-10–producing 
CD24hiCD27+ Bregs was also reported in patients with allergic rhi-
nitis (9). Other studies evaluating Bregs in patients with milk aller-
gy have demonstrated a decrease in IL-10–producing CD5+ B cells 
upon in vitro restimulation with casein. In contrast, this population 
of Bregs remained unchanged or increased in the milk-tolerant 
group (62, 63). Similar observations were observed in beekeepers 
who exhibited tolerance to the bee venom allergen phospholipase 
A2 (PLA2). PLA2-specific Br1 cells produced allergen-specific IgG4 
antibodies and suppressed allergen-specific T cell responses in an 
IL-10–dependent manner (19).
Cancer. Studies from mouse models have provided extensive 
evidence supporting an important role for Bregs in tumor immunol-
ogy. In a mouse model of breast cancer, a subset of CD25hiCD69hi 
tumor-evoked Bregs was reported to facilitate lung metastasis by 
inducing the differentiation of FoxP3+ Tregs in a TGF-β–dependent 
manner (64). Interestingly, tumor-evoked Bregs expressed high 
levels of CD80 and CD86, suggesting that CD80- and CD86-me-
diated contact between Bregs and their target cells is important 
both in suppression of effector T cell response and in the differen-
tiation of Breg-induced Tregs. More recently, it has been suggested 
that tumor-infiltrated B cells develop immune-suppressive prop-
erties via enhanced expression of TGF-β, PD-L1, CD86, and IL-10 
(65). In this model, tumor-infiltrating B cells that were not initially 
intrinsically suppressive developed a Breg phenotype upon expo-
sure to the tumor microenvironment (65). Some of the identified 
factors promoting a Breg phenotype are tumor-derived metabolites 
of 5-lipoxygenase in a breast cancer model, and placental growth 
factor (PIGF) in gliomas (66, 67). The role of Bregs in promoting 
tumor progression is supported by the finding that IL-10–produc-
ing Bregs inhibit lymphoma depletion during anti-CD20 therapy 
in mice (68). Thus far, there are very few reports on the role of 
Bregs in human cancer studies. Granzyme B–expressing (GZMB- 
expressing) human B cells with a CD38+CD1d+IgM+CD147+ pheno-
type have been shown to infiltrate tumors and inhibit CD4+ T cell 
responses (14). GZMB+ Bregs were induced by IL-21–producing T 
cells and also expressed IL-10, IDO, and CD25 (14). Both GZMB+ 
B cells and IL-21+ T cells were identified within the microenviron-
ment of various tumor types, including breast, cervical, and ovar-
Rheumatoid arthritis. In patients with RA, CD24hiCD38hi Bregs 
are numerically impaired in comparison with healthy individuals 
and fail to suppress Th17 responses and convert CD4+ T cells into 
Tregs (6). The frequency of Bregs in RA patients was shown to nega-
tively correlate with disease activity. In agreement with this finding, 
three recent studies have reported reduced frequencies of B10 cells, 
IL-10+TIM1+ B cells, and IL-10+CD5+CD1dhi B cells in RA patients 
compared with healthy controls (48–50). In contrast, one study 
reported an increase in IL-10+ Bregs in RA patients compared with 
healthy controls (51). The disparity between the studies is likely due 
to the differences in stimuli used for inducing IL-10 production by 
B cells in vitro. Whereas the studies showing a decrease in IL-10+ 
Bregs used either TLR or CD40 activation of B cells, the study 
reporting an increase in Bregs used CD40 ligation in combination 
with TLR activation. It is possible that using this combination of 
stimuli may overcome the defects shown in the previous studies.
Other autoimmune diseases. Studies of patients with other 
autoimmune diseases are extremely limited in comparison with 
SLE, MS, or RA.
In patients with pemphigus, an organ-specific autoimmune 
bullous disease (52), CD24hiCD38hi B cells displayed reduced 
IL-10 production upon long-term stimulation and a significantly 
decreased ability to suppress Th1 responses (10). Interest-
ingly, rituximab-treated pemphigus patients who responded 
to therapy displayed increased frequencies of CD24hiCD38hi 
B cells and IL-10 production compared with untreated patients 
or patients not responding to therapy (53). It is possible that 
Bregs may contribute to restoration of tolerance in rituximab- 
responsive pemphigus patients.
Inflammatory bowel disease is a chronic inflammatory dis-
ease that has two major clinically defined forms: Crohn’s disease 
and ulcerative colitis (54). In patients with both Crohn’s disease 
and ulcerative colitis compared with healthy controls, IL-10–pro-
ducing Bregs are significantly reduced in frequency (11). Similar 
findings have been reported in patients with type 1 diabetes (55), 
psoriasis (26), and systemic sclerosis (56, 57), in which decreas-
es in suppressive IL-10–producing Bregs have been associated 
with progression of disease. While further studies are required 
to understand the mechanisms of Breg-mediated suppression in 
these diseases, there is sufficient evidence to conclude that Bregs 
are numerically deficient in autoimmune diseases and possibly 
contribute to the loss of immune tolerance.
Infection. The role of Bregs in bacterial and parasitic infections 
has been discussed in detail elsewhere (58). Here, we focus on the 
role of human Bregs in the immune response during viral infections, 
such as HIV and HBV infection. In patients infected with HIV, an 
increase in IL-10–producing CD24hiCD38hi Bregs has been shown 
to correlate positively with the viral load (59). In the same paper, 
Bregs were shown to suppress HIV-1–specific CD8+ T cell responses 
in an IL-10– and PD-L1–dependent manner (59). The suppressive 
role of Bregs during HIV infection was confirmed by depletion of 
Bregs from peripheral blood mononuclear cells (PBMCs) in vitro, 
which resulted in restored CD8+ T cell effector function as well as 
clearance of infected CD4+ T cells (59). Similarly, the frequency of 
another subset of IL-10–producing Bregs with a CD19+TIM1+ phe-
notype has been shown to correlate with viral load and effectively 
inhibit HIV-specific T cell responses in an IL-10–dependent manner 
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subsequently underwent rejection events (71). Further evidence 
of the importance of Bregs in transplant tolerance has been shown 
in a recent prospective study in renal transplant patients, where 
increased CD24hiCD38hi B cell numbers were found to be associat-
ed with reduced rejection rates (72). Interestingly, cord blood (CB) 
has been identified as a rich source of immunosuppressive Bregs 
(73). CB-derived Bregs have been shown to protect CB transplant 
recipients from cGVHD disease. Altogether, these studies support 
a role for Bregs as a biomarker for transplantation tolerance and 
shed some light on its therapeutic potential.
Therapeutic potential of Bregs
The majority of current treatments for various immune-related 
pathologies target the symptoms of the conditions rather than offer 
cures. Moreover, most treatments remain toxic and ineffective 
when given to the patient over a long period of time. In the context 
of autoimmunity, long-term use of steroids and immunosuppres-
sive drugs increases the risk of life-threatening infections. For these 
reasons, cellular immunotherapy involving highly targeted remov-
al or modification of only those immune cells that drive disease 
progression is becoming increasingly popular. This approach has 
already proven highly effective in the treatment of various cancers, 
with its low toxicity and increased ability to eradicate tumors (74). 
ian carcinomas (14). These findings are particularly significant, as 
they confirm the existence of B cells with a regulatory phenotype 
in solid tumor infiltrates, where they would suppress antitumor 
immune responses. Improved understanding of Breg induction 
and function in tumor immunology could result in Breg-targeted 
therapies that enhance antitumor immunity.
Transplantation. CD24hiCD38hi Bregs appear to play an import-
ant role in establishing transplant tolerance by suppressing effector 
T cell responses (69). In studies of allogeneic hematopoietic stem 
cell transplant recipients, Bregs from patients with chronic graft-
versus-host disease (cGVHD) displayed reduced IL-10–produc-
ing capacity compared with patients without cGVHD and healthy 
donors (7). Furthermore, renal transplant recipients with stable 
graft function have been reported to display significantly higher 
levels of IL-10–producing CD24hiCD38hi Bregs than immunosup-
pressed patients, and these levels were comparable to healthy 
controls (70). More recently, the ratio of IL-10/TNF-α expression 
by CD24hiCD38hi B cells, as a measure of the cytokine polarization 
of Bregs, has been shown to be a better indicator of Breg function 
than IL-10 expression alone (71). Whereas there was no difference 
in CD24hiCD38hi B cell IL-10 expression between renal transplant 
patients with stable graft function and those patients showing graft 
rejection, the IL-10/TNF-α ratio was lower in those patients who 
Figure 2. Potential Breg-targeted therapies. Therapeutic interventions targeting Bregs could provide improved approaches for the treatment of 
immune-mediated diseases. (i) Ex vivo expansion of Bregs. Stimulation of B cells isolated from patient-derived PBMCs to expand Bregs, followed by 
adoptive transfer of FACS-sorted Bregs, could suppress inflammation and reestablish tolerance. (ii) In vivo modulation to expand Bregs. The recent iden-
tification of stimuli that induce Breg differentiation provides new opportunities to induce a shift in B cells toward a more regulatory or antiinflammatory 
phenotype. (iii) Depletion of Bregs or Beffs. Targeted depletion of specific B cell subsets would provide more advantages over currently used total B cell 
depletion therapies in the treatment of cancers and other immune disorders.
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As detailed above, Bregs are important modulators of the immune 
response and promote immunological tolerance. Whereas cer-
tain conditions such as autoimmune diseases and transplantation 
require an expansion of immunosuppressive Bregs, other diseases 
such as cancers and chronic infections may benefit from Breg deple-
tion (75). Thus, strategies designed to isolate, expand, infuse, or 
deplete Bregs would provide a new window of opportunity to treat 
various immune-mediated disorders (summarized in Figure 2).
Depletion of Bregs. The use of B cell depletion therapy (i.e., rit-
uximab) has shown some success in the treatment of autoimmune 
diseases (43, 44). However, elimination of all B cells to treat auto-
immunity is disadvantageous, as it results in the depletion of Bregs 
that suppress inflammation. It would therefore be advantageous 
to be able to selectively deplete Bregs or effector B cell subsets 
depending on the disease context. One of the major limiting fac-
tors to using this approach is the lack of surface markers specific 
for Bregs. Although several markers, alone or in combination, have 
been shown to identify the majority of IL-10–producing Bregs, they 
are not sufficiently Breg-specific to use in cellular therapy (4, 13, 
15, 76). Identification of Breg-specific markers could result in the 
development of depletion therapies specifically targeting Bregs or 
effector B cells (Beffs). For example, enhanced expression of PD-L1 
by tumor-infiltrated B cells (a trait particularly attributed to Bregs) 
provided a rationale for PD-1 blockade in the treatment of malig-
nant B cell lymphomas (77). PD-1 blockade has been reported as 
highly effective in the treatment of refractory Hodgkin’s disease 
and partially effective in the treatment of patients with relapsed 
diffuse large B cell lymphoma (78, 79). Collectively, this suggests 
that new therapies targeting Breg activity could be a promising 
approach to treat certain cancers and chronic infections.
In vivo manipulation or ex vivo expansion of Bregs. Recent 
emerging evidence suggests that the environmental milieu in 
which B cells differentiate plays a pivotal role in the induction of 
Bregs. In addition to CD40, TLR, and BCR signaling, which are 
known to be important for Breg activation and function, there 
is emerging evidence suggesting that inflammatory cytokines 
play a critical role in the induction of immunosuppressive Bregs. 
For example, an expansion of Bregs is observed upon exposure 
to inflammatory cytokines, such as IL-1β, IL-6, IL-21, IFN-β, 
IFN-α, and B cell activating factor (BAFF) (18, 32, 33, 35, 80, 81). 
This effect is further enhanced by coactivation via TLRs and/or 
CD40 (18, 82, 83). While these studies support the possibility of 
in vivo expansion of Bregs, stimuli such as inflammatory cyto-
kines carry the potential risk of triggering undesirable proin-
flammatory responses from various cell types. The possibility 
of serious adverse effects that can arise from systemic admin-
istration of these cytokines must be taken into consideration. 
Indeed, the expansion of Bregs by proinflammatory cytokines 
appears to be tightly regulated by the strengths of the signals 
that they receive; using the wrong concentration of the proin-
flammatory cytokine may lead to effector rather than regulatory 
B cell expansion. In patients with autoimmunity, chronic expo-
sure of B cells to elevated levels of proinflammatory cytokines 
results in a reduction in functional Bregs that are unable to 
restore tolerance (18). Importantly, antiinflammatory cytokines 
may also be important in the differentiation of Bregs. In a mouse 
model of experimental autoimmune uveitis, the antiinflamma-
tory cytokine IL-35 has been shown to induce a population of 
Bregs that suppress development and progression of disease 
(84). Additionally, commensal bacteria have been reported to 
play a role in Breg expansion. In arthritic mice, gut microbio-
ta–induced IL-1β and IL-6 production directly promoted Breg 
differentiation and IL-10 production (32). The importance of 
microbiota in the expansion of Bregs was confirmed in mice 
treated with antibiotics that displayed a decrease in Breg num-
bers compared with untreated mice. Thus, better understanding 
of the signals that drive Breg expansion could provide new and 
improved strategies for the in vivo expansion of Bregs.
Challenges and outstanding questions
Therapies targeted to modify Bregs show great potential in the 
treatment of autoimmune diseases, cancers, and chronic infec-
tions. However, there are several issues that must be addressed in 
order to develop Breg-targeted therapies:
Plasticity and stability of Bregs. How do we ensure that adop-
tively transferred Bregs maintain their phenotype and function 
in vivo? Breg subsets have been identified at different stages of B 
cell development, from an early immature stage to a late plasma 
cell stage (4, 15, 84). These multiple Breg subsets could repre-
sent a unique functional Breg lineage that changes phenotype in 
response to the microenvironmental input. It is unknown whether 
Bregs develop into Beffs under chronic inflammatory conditions. 
At present, only one study, using mouse models, reports that Bregs 
differentiate into antibody-secreting cells after transient IL-10 
production in vivo (85). Further investigations on the plasticity 
and functional stability of Bregs are necessary to understand how 
to maintain a prolonged Breg phenotype.
Stimuli to expand Bregs. Activation via BCR, TLR, or CD40, as 
well as cytokines, has been shown to activate and expand Bregs. 
Furthermore, different combinations of stimuli have been used 
to quantify Bregs in various diseases. It would be important to 
compare the different stimuli used in order to identify stimuli that 
uniquely expand Bregs but not proinflammatory responses from 
other cell types. We also need to understand whether modulating 
signals in vivo can provide a long-term favorable environment for 
Breg differentiation.
Efficient transfer of Bregs. Another important question is what 
quantity of Bregs to transfer for effective therapy; while too few 
Bregs may be insufficient to suppress inflammation, too many 
Bregs could result in increased immune suppression–related dis-
orders such as cancer and risk of infection flares. Moreover, how 
can we ensure that the transferred Bregs will travel to the target 
site and suppress disease? To treat diseases such as RA, it is crucial 
that the Bregs migrate to the inflamed joints. While there is some 
evidence from murine studies showing that Bregs migrate to sites 
of inflammation (65), this requires further evaluation. It must be 
noted that while in vitro culture studies provide an indication of 
Breg function in vivo, they are not truly representative of Bregs at 
the site of inflammation. For instance, the stimuli used to expand 
and identify Bregs in vitro might be different from stimuli in the 
surrounding tissue microenvironment. Further efforts to charac-
terize Bregs directly from patient material, particularly at the site 
of inflammation, are vital in understanding the role of Bregs in dif-
ferent disease states.
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Efficacy of Breg therapies compared with immunosuppressive thera-
pies. Finally, would Breg therapy provide a more effective treatment 
than current immunosuppressive regimens? The improved man-
agement of various diseases using current treatments would require 
Breg-targeted treatment to provide long-term cure with minimal 
side effects. Future research efforts to address these questions will 
pave the way for novel Breg-based cellular therapies.
Conclusion
Over the past decade a wealth of studies have demonstrated that 
Bregs are crucial in the maintenance of immune tolerance and in the 
suppression of inflammation. We have discussed our understand-
ing of human Bregs and proposed several therapeutic strategies 
targeting Bregs for improved management of immune- mediated 
disorders. Despite the presently unanswered questions and theoret-
ical risks, the future of Breg-targeted therapies shows great prom-
ise and could provide a more improved approach to treat various 
immune-related pathologies. Further investigation into developing 
Breg-based immunotherapies could enable their application for the 
treatment of immune disorders in the forthcoming decade.
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